Cspc Hits 5: week high on US FDA's nod on herpes zoster vaccine trial
BUZZ-CSPC hits 5-week high on US FDA's nod on herpes zoster vaccine trial ** Shares of CSPC Pharmaceutical Group 1093.HK climb 4.6% to HK$9.91, their highest level since August 26
** Stock on track for the biggest one-day pct gain since September 21 in the third straight rising session
** Top pct gainer in benchmark Hang Seng Index .HSI, which slips 0.4%
** CSPC says its Recombinant Herpes Zoster Vaccine (SYS6052) for prevention of herpes zoster has obtained approval from the U.S. Food and Drug Administration to conduct relevant clinical trials in the US
** CSPC also says Phase Ib clinical trial of JMT206 Injection for weight management in adult patients with overweight or obesity has been officially initiated at the first study centre in China
** YTD, stock up 16%, Hang Seng Biotech Index .HSBIO up 15%
(Reporting by Donny Kwok)
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines